Meeting Banner
Abstract #3795

Quantitative, semiautomatic comparison of ferumoxytol and gadoteridol enhancement in treated glioma patients

Andrea Horváth1, Csanad Varallyay1, Daniel Schwartz1, Joao Prola Netto1, Peter Varallyay2, Laszlo Szidonya1, Gerda Toth1, Rongwei Fu1, Prakash Ambady1, Peter Bogner3, and Edward Neuwelt1

1Oregon Health and Science University, Portland, OR, United States, 2National Institute of Clinical Neurosciences, Budapest, Hungary, 3University of Pécs, Pécs, Hungary

Ferumoxytol is a nano-sized iron oxide particle approved for iron replacement therapy and may be used off label as an MRI contrast agent. While gadolinium-based contrast agents leak into the brain parenchyma where the blood brain barrier is not intact several minutes after administration, ferumoxytol remains intravascular for hours due to its high molecular weight, enabling excellent vascular visualization, with visible parenchymal enhancement peaking 24 hours after administration. In this study, we compared ferumoxytol T1 enhancement to standard of care gadoteridol enhancement with a quantitative method, which is an important step to develop ferumoxytol as an alternative MR imaging agent.

This abstract and the presentation materials are available to members only; a login is required.

Join Here